Bridgebio Pharma Inc Earnings

Bridgebio Pharma Inc’s revenue fell -44.76% since last year same period to $116.63Mn in the Q1 2025. On a quarterly growth basis, Bridgebio Pharma Inc has generated 1882.88% jump in its revenue since last 3-months.

Bridgebio Pharma Inc’s net profit fell -375.41% since last year same period to $-167.42Mn in the Q1 2025. On a quarterly growth basis, Bridgebio Pharma Inc has generated 36.83% jump in its net profits since last 3-months.

Bridgebio Pharma Inc’s net profit margin fell -760.56% since last year same period to -143.55% in the Q1 2025. On a quarterly growth basis, Bridgebio Pharma Inc has generated 96.81% jump in its net profit margins since last 3-months.

Bridgebio Pharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.89 - a 18.35% jump from last quarter’s estimates.

Bridgebio Pharma Inc’s earning per share (EPS) estimates for the current year stand at -0.89.

Bridgebio Pharma Inc’s earning per share (EPS) fell -394.4% since last year same period to -0.99 in the Q1 2025. This indicates that the Bridgebio Pharma Inc has generated -394.4% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Bridgebio Pharma Inc’s return on assets (ROA) stands at -0.48.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Bridgebio Pharma Inc’s return on equity (ROE) stands at -17.9.